The book “Breast Cancer: Current Trends in Molecular Research” summarize the most recent developments in the field of breast cancer. This book is targeted at a broad audience who is interested in breast cancer research and treatment. Chapters are emphasized to incorporate the recent breast cancer research and etiology, diagnosis, and treatment, are included in the entire book. Bioinformatics resources added to unearth new and updated data on breast cancer signaling, immune responses, DNA damage, and epigenetic alterations. Big data in cancer research has become a reality, and a chapter has been added to describe the data resources available to breast cancer researchers. This book provides readers with access to data from a variety of immunotherapy and gene therapy studies. A chapter on the use of nanotechnology in breast cancer has been added to assist readers in delving into nanotechnology, which has resulted in a paradigm shift in targeted drug delivery in breast cancer.
Breast cancer science is shaped continuously by new technologies and new findings, and as such the importance of dietary polyphenol and its role will help to solve key breast cancer research questions. Introducing these new topics to cancer research will help identify areas requiring more attention and research. The application of radiotherapy in breast cancer is also well described, which will assist in developing the concept of clinical radiotherapy. In this book, current research on developing new minimally invasive surgical modalities and new radiation modalities with minimal side effects have been included. Overall, the chapters are organized to provide readers with a convenient and effective way to familiarize themselves with the latest research in the field of breast cancer. However, it is important to remember that progress in research does not occur as isolated events, but rather from a body of knowledge that builds up over time. The book chapters included will help all future breast cancer researchers as a repository of information. This book also offers a unique forum for researchers from different disciplines to synthesize distinct approaches and ideas, discuss the most recent scientific advances, and contextualize them within the greater framework of breast cancer research and oncology in society.
About the Editor:
Dr. Shankar Suman, Ph.D. is a researcher in cancer biology. He has worked to delineate complex metabolic and proteomic pathways in classifying the heterogenicity of breast cancer. Currently, Dr. Suman is a researcher at the Ohio State University, Ohio. He served as a lead author in several articles, and he also edited a previous book entitled “Current Advances in Breast Cancer Research: A Molecular Approach”. He is a part-time reviewer in many prestigious journals of Elsevier, Frontiers, PLoS, and Wiley publications and guest associate editor in Frontiers in Genetics. Dr. Suman is also a member of the American Association for Cancer Research (AACR) and the American Society for Biochemistry and Molecular Biology (ASBMB), like prestigious societies. His current interest is to study various signaling pathways in drug acquired resistivity in cancer cells.
Dr. Shivam Priya is a research fellow at the Ohio State University Comprehensive Cancer Center, USA. He holds a PhD degree in Biotechnology from Integral University, India. After completing his PhD, he obtained postdoctoral research training at the Hebrew University, Israel. His research focuses are in molecular and cell biology, especially signaling pathways in cancer such as receptor tyrosine kinases, MAPK and apoptosis. These signaling cascades control gene expression programs that determine essential cellular functions such as proliferation or arrest of cell proliferation, cell shape and motility, and cell fate. Deregulation of these signaling pathways can lead to cancer. His major research interests are stem cell biology, epigenetics and immunology, reinforced as a researcher. Dr. Priya has presented his research finding at various national and international conferences, seminars, and workshops. He also serves as a reviewer for many prestigious journals and a member of many respected cancer societies.
Dr. Akanksha Nigam earned her Ph.D. degree in Biotechnology from Integral University, India. She completed her first postdoctoral research training at the Hebrew University, Israel, and then she moved to Stefanie Spielman Comprehensive Breast Center, The Ohio State University Comprehensive Cancer Center, the USA to conduct research on breast cancer biology. She has overall expertise in cancer biology and cell signaling. Her key research focuses on invasive lobular cancer (ILC). She has published several research and review articles in reputed journals and serves as a key author of several book chapters as well.
Breast cancer, Targeted Therapeutics, Epithelial-Mesenchymal Transition, Nanoparticles, DNA Damage Response, Polyphenols, DNA Repair, Radiotherapy, Cancer Immunoediting, Virtual Simulation, Tumoricidal, Hormonal therapy, Reactive nitrogen species, Immunotherapy, Tumor-associated antigens, Bioinformatics, Biomarkers, High-throughput sequencing, Epigenetics, Nitric oxide.
For more information please visit: https://bit.ly/3PBXUn5